Fig. 10From: First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysisThe cost-effectiveness acceptability curves of patients with non-epithelioid histology. CE Cost-effectiveness, N Patients with non-epithelioid histology, NI Nivolumab plus ipilimumab, C Pemetrexed plus cisplatin/carboplatinBack to article page